KHKim van Den Hoek

Kim van Den Hoek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kim van Den Hoek has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of microbiota profiles of fecal samples, rectal swabs and mucosal biopsies in patients with inflammatory bowel disease

    by Tessel M. van Rossen, Kim van Den Hoek, Thomas Groot, Rob H. Creemers, Maysa L. M. van Doorn-Schepens, Emma M. van Andel, Matthijs E. Grasman, Nanne K. H. de Boer, Gerd Bouma, Andries E. Budding, et al.

    Gut microbiota changes are associated with inflammatory bowel disease (IBD). In most microbiota studies, intestinal microbiota composition is examined in fecal samples, but their representativeness of mucosa-associated microbiota at inflammation sites remains unclear. This study aimed to explore microbiota composition in different IBD sample types and assess their interchangeability for research and clinical use. Multicentre, prospective, observational study including 200 IBD patients (518 samples). We compared microbiota profiles from faeces, rectal swabs and mucosal biopsies from different colon sites. Microbiota composition was analyzed by Molecular Culture™, a bacterial profiling technique based on species-specific differences in the 16S-23S interspace region of bacterial ribosomal DNA, with taxonomic classification by phylum-specific fluorescent PCR primers. Fecal samples and rectal swabs contained a higher microbial diversity and abundance than colonic biopsies. Microbiota compositions of different sample types within an individual happened to be quite dissimilar (median cosine similarities 0.43–0.53). Within individuals, biopsies from the same location in the colon were just as similar as biopsies from different locations (median cosine similarities 0.85 vs. 0.82, respectively). Fecal samples, rectal swabs and colonic biopsies of an individual show distinct microbiota profiles and should not be used interchangeably in microbiota studies or clinical applications.


  • Open Access

    Optimizing duodenal tissue acquisition for mechanistic studies of duodenal ablation in type 2 diabetes

    by Celine B.E. Busch, Kim van Den Hoek, E. Andra Neefjes-Borst, Max Nieuwdorp, Annieke C.G. van Baar, Jacques J.H.G.M. Bergman

    Histological analysis of regular duodenal biopsies to study morphologic changes after duodenal ablation for type 2 diabetes (T2D) and metabolic syndrome is hampered by variability in tissue orientation. We designed an optimized tissue acquisition protocol using duodenal cold snare resections to create tissue microarrays (TMAs) and to allow for single-cell RNA sequencing (scRNA-seq).The open-label DIRECT study included patients undergoing an upper gastrointestinal interventional endoscopy for non-duodenal indications. All underwent one ot two single-piece duodenal cold snare resections. Endpoints were safety, adequate histological orientation of specimen and TMA, and tissue dissociation quality for scRNA-seq. The optimized tissue acquisition protocol was validated in a duodenal ablation study, EMINENT-2.In DIRECT, nine patients were included in whom a total of 16 cold snare resections were obtained. No severe adverse events (SAEs) occurred. Eighty percent of specimens and corresponding TMAs showed optimal tissue orientation. Further improvement was achieved by reducing tissue damage during endoscopic retrieval and improving histologic evaluation by eliminating ink use and pinning the tissue on cork. High-quality tissue dissociation scores for scRNA-seq were achieved in 13 of 18 samples (72%). In EMINENT-2, 38 cold snares were obtained without SAEs, histopathologic analysis showed good orientation in all samples, and dissociation scores for scRNA-seq were qualified in 35/38 (92%) samples.Duodenal cold snare resection is safe and can provide high-quality tissue for optimally oriented TMAs and high-quality tissue dissociation scores for scRNA-seq (Clinicaltrials.gov, NCT06333093, NCT05984238). This approach will allow mechanistic studies about the effects of duodenal ablation on metabolic syndrome and T2D.